Xiaoliang Li , Xizhu Xu , Jichen Li , Huanhuan Lu , Congcong Wang , Rui Wang , Jinbo Xiao , Ying Liu , Yang Song , Jingdong Song , Qiang Sun , Yong Zhang
{"title":"中国优势流行病D3基因型柯萨奇病毒A6候选病毒样颗粒疫苗的制备及其免疫保护作用","authors":"Xiaoliang Li , Xizhu Xu , Jichen Li , Huanhuan Lu , Congcong Wang , Rui Wang , Jinbo Xiao , Ying Liu , Yang Song , Jingdong Song , Qiang Sun , Yong Zhang","doi":"10.1016/j.bsheal.2023.11.001","DOIUrl":null,"url":null,"abstract":"<div><p>Coxsackievirus A6 of the D3a genotype (CVA6 D3a) is a primary pathogen causingmainland of China's hand, foot, and mouth disease (HFMD). Viral-like particle (VLP) vaccines represent a potential candidate vaccine to prevent HFMD. This study collected Anti-CVA6 D3a VLPs serum from BALB/c female mice immunized using CVA6 D3a VLPs. The neutralizing antibody levels were compared against the representative 14-JX2018 (D3a) and N4-YN2015 (D3b) strains between the antisera of different immune pathways. The immunoprotective effect of anti-CVA6 D3a VLPs against these strains was monitored using pathological sections and immunohistochemical results of lung and skeletal muscle tissues in seven-day-old Institute of Cancer Research (ICR) mice. Immunological protection against different branches of viruses was evaluated in 7-day-old (serum passive immune protection) and 14-day-old (VLPs active immune protection) neonatal ICR mice models. Serum-neutralizing antibody levels were positively correlated with the number of immunizations and higher against 14-JX2018 than against N4-YN2015. Furthermore, these levels were significantly higher with abdominal injection than intramuscular injection. The immunized serum of 7-day-old ICR mice inoculated three times was 100 % protected against CVA6 D3a 14-JX2018 (lethal titer: 10<sup>6.25</sup> TCID<sub>50</sub>) and CVA6 D3b N4-YN2015 (lethal titer: 10<sup>5.25</sup>TCID<sub>50</sub>) fatal attacks, respectively. For ICR mice that have completed two active immunizations for 14 days, both CVA6 D3a 14-JX2015 (challenge titer: 10<sup>8.25</sup> TCID<sub>50</sub>) and CVA6 D3b N4-YN2015 (challenge titer: 10<sup>7.25</sup> TCID<sub>50</sub>) were used for the challenge, and the mice were able to survive. Overall, the CVA6 D3a VLPs prepared in this study are a potential vaccine candidate for CVA6, as it has the optimal protective effect against both CVA6 D3a and D3b evolutionary branches viruses.</p></div>","PeriodicalId":36178,"journal":{"name":"Biosafety and Health","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590053623001301/pdfft?md5=d73fb1c5fc096cd13631fe46e9e53c53&pid=1-s2.0-S2590053623001301-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Preparation and immunoprotective effects of a virus-like particle candidate vaccine of the dominant epidemic D3 genotype coxsackievirus A6 in China\",\"authors\":\"Xiaoliang Li , Xizhu Xu , Jichen Li , Huanhuan Lu , Congcong Wang , Rui Wang , Jinbo Xiao , Ying Liu , Yang Song , Jingdong Song , Qiang Sun , Yong Zhang\",\"doi\":\"10.1016/j.bsheal.2023.11.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Coxsackievirus A6 of the D3a genotype (CVA6 D3a) is a primary pathogen causingmainland of China's hand, foot, and mouth disease (HFMD). Viral-like particle (VLP) vaccines represent a potential candidate vaccine to prevent HFMD. This study collected Anti-CVA6 D3a VLPs serum from BALB/c female mice immunized using CVA6 D3a VLPs. The neutralizing antibody levels were compared against the representative 14-JX2018 (D3a) and N4-YN2015 (D3b) strains between the antisera of different immune pathways. The immunoprotective effect of anti-CVA6 D3a VLPs against these strains was monitored using pathological sections and immunohistochemical results of lung and skeletal muscle tissues in seven-day-old Institute of Cancer Research (ICR) mice. Immunological protection against different branches of viruses was evaluated in 7-day-old (serum passive immune protection) and 14-day-old (VLPs active immune protection) neonatal ICR mice models. Serum-neutralizing antibody levels were positively correlated with the number of immunizations and higher against 14-JX2018 than against N4-YN2015. Furthermore, these levels were significantly higher with abdominal injection than intramuscular injection. The immunized serum of 7-day-old ICR mice inoculated three times was 100 % protected against CVA6 D3a 14-JX2018 (lethal titer: 10<sup>6.25</sup> TCID<sub>50</sub>) and CVA6 D3b N4-YN2015 (lethal titer: 10<sup>5.25</sup>TCID<sub>50</sub>) fatal attacks, respectively. For ICR mice that have completed two active immunizations for 14 days, both CVA6 D3a 14-JX2015 (challenge titer: 10<sup>8.25</sup> TCID<sub>50</sub>) and CVA6 D3b N4-YN2015 (challenge titer: 10<sup>7.25</sup> TCID<sub>50</sub>) were used for the challenge, and the mice were able to survive. Overall, the CVA6 D3a VLPs prepared in this study are a potential vaccine candidate for CVA6, as it has the optimal protective effect against both CVA6 D3a and D3b evolutionary branches viruses.</p></div>\",\"PeriodicalId\":36178,\"journal\":{\"name\":\"Biosafety and Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590053623001301/pdfft?md5=d73fb1c5fc096cd13631fe46e9e53c53&pid=1-s2.0-S2590053623001301-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biosafety and Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590053623001301\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosafety and Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590053623001301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
Preparation and immunoprotective effects of a virus-like particle candidate vaccine of the dominant epidemic D3 genotype coxsackievirus A6 in China
Coxsackievirus A6 of the D3a genotype (CVA6 D3a) is a primary pathogen causingmainland of China's hand, foot, and mouth disease (HFMD). Viral-like particle (VLP) vaccines represent a potential candidate vaccine to prevent HFMD. This study collected Anti-CVA6 D3a VLPs serum from BALB/c female mice immunized using CVA6 D3a VLPs. The neutralizing antibody levels were compared against the representative 14-JX2018 (D3a) and N4-YN2015 (D3b) strains between the antisera of different immune pathways. The immunoprotective effect of anti-CVA6 D3a VLPs against these strains was monitored using pathological sections and immunohistochemical results of lung and skeletal muscle tissues in seven-day-old Institute of Cancer Research (ICR) mice. Immunological protection against different branches of viruses was evaluated in 7-day-old (serum passive immune protection) and 14-day-old (VLPs active immune protection) neonatal ICR mice models. Serum-neutralizing antibody levels were positively correlated with the number of immunizations and higher against 14-JX2018 than against N4-YN2015. Furthermore, these levels were significantly higher with abdominal injection than intramuscular injection. The immunized serum of 7-day-old ICR mice inoculated three times was 100 % protected against CVA6 D3a 14-JX2018 (lethal titer: 106.25 TCID50) and CVA6 D3b N4-YN2015 (lethal titer: 105.25TCID50) fatal attacks, respectively. For ICR mice that have completed two active immunizations for 14 days, both CVA6 D3a 14-JX2015 (challenge titer: 108.25 TCID50) and CVA6 D3b N4-YN2015 (challenge titer: 107.25 TCID50) were used for the challenge, and the mice were able to survive. Overall, the CVA6 D3a VLPs prepared in this study are a potential vaccine candidate for CVA6, as it has the optimal protective effect against both CVA6 D3a and D3b evolutionary branches viruses.